Circio invites to R&D and corporate update webcast on 4 December 2024
- CEO Dr. Erik D Wiklund will provide a company update and information related to the upcoming warrant exercise period
- CTO Dr. Thomas B Hansen will present the most recent circVec in vitro and in vivo data and an overview of Circio´s R&D strategy
Oslo, Norway 28 November 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CEST on Wednesday 4 December 2024. In the webcast, Circio management will provide a corporate update and showcase the latest developments for the circVec platform technology. Practical information relating to the warrant exercise period in connection with the rights issue completed during June-July 2024 will also be provided.
Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen
Time: 10:00 CEST on 4 December 2024
Click here to access Teams webcast
Meeting ID: 349 042 796 001
Passcode: 2PM24NF6
Questions can be submitted in advance by email to: erik.wiklund@circio.com or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Neil Hunter - Hunter PR
Phone:+44 7821 255568
Email: neiljameshunter@gmail.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.